John Hussman's CRSP Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 10,500 shares of CRISPR Therapeutics AG (CRSP) worth $580,860, representing 0.12% of the portfolio. First purchased in 2019-Q4, this medium-term investment has been held for 18 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in CRSP, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2020, adding 15,250 shares. Largest reduction occurred in Q4 2020, reducing 20,400 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's CRISPR Therapeutics (CRSP) Holding Value Over Time
Track share changes against reported price movement
Quarterly CRISPR Therapeutics (CRSP) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +10,500 | New Buy | 10,500 | $55.32 |
| Q4 2023 | -9,300 | Sold Out | 0 | $0.00 |
| Q2 2023 | -7,300 | Reduce 43.98% | 9,300 | $56.14 |
| Q4 2022 | +6,200 | Add 59.62% | 16,600 | $40.65 |
| Q3 2022 | -10,400 | Reduce 50.00% | 10,400 | $65.38 |
| Q2 2022 | +10,400 | Add 100.00% | 20,800 | $60.77 |
| Q4 2021 | -2,000 | Reduce 16.13% | 10,400 | $75.77 |
| Q3 2021 | +3,100 | Add 33.33% | 12,400 | $111.94 |
| Q2 2021 | +5,700 | Add 158.33% | 9,300 | $161.94 |
| Q1 2021 | -6,600 | Reduce 64.71% | 3,600 | $121.94 |
| Q4 2020 | -20,400 | Reduce 66.67% | 10,200 | $153.14 |
| Q3 2020 | +15,250 | Add 99.35% | 30,600 | $83.63 |
| Q1 2020 | +5,100 | Add 49.76% | 15,350 | $42.41 |
| Q4 2019 | +10,250 | New Buy | 10,250 | $60.88 |
John Hussman's CRISPR Therapeutics Investment FAQs
John Hussman first purchased CRISPR Therapeutics AG (CRSP) in Q4 2019, acquiring 10,250 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held CRISPR Therapeutics AG (CRSP) for 18 quarters since Q4 2019.
John Hussman's largest addition to CRISPR Therapeutics AG (CRSP) was in Q3 2020, adding 30,600 shares worth $2.56 M.
According to the latest 13F filing for Q3 2026, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 10,500 shares of CRISPR Therapeutics AG (CRSP), valued at approximately $580,860.
As of the Q3 2026 filing, CRISPR Therapeutics AG (CRSP) represents approximately 0.12% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in CRISPR Therapeutics AG (CRSP) was 30,600 shares, as reported at the end of Q3 2020.